Short answer
Beta Bionics, Inc. (BBNX) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $27M with net income of −$14M.
Q3 2025 key financials · XBRL
- Revenue
- $27M
- +17.3% QoQ
- Net income
- −$14M
- +15.8% QoQ
- Operating margin
- -62.5%
- Gross margin
- 55.5%
- EPS (diluted)
- −$0.29
- +3.3% QoQ
Source: XBRL data from the Beta Bionics, Inc. (BBNX) Q3 2025 10-Q on SEC EDGAR. USD.
Beta Bionics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- PBP channel strongest growth, representing 21% of nine-month net sales vs 9% YoY
- Approximately 70% of adoption came from prior MDI users vs 67% YoY
- Phase 3 collaboration payments totaled $2.5 million as of September 30, 2025
Risk Factors
- Revenue concentration: top four DME distributors represented approximately 52% of total sales for nine months ended September 30, 2025
- Liquidity risk: $274.0 million in cash, equivalents and investments estimated sufficient through first half of 2028
- Loss risk: net loss $59.7 million and accumulated deficit $356.5 million as of September 30, 2025
- Regulatory risk: additional indications, including T2D and bihormonal iLet, require future FDA authorization
- Competitive risk: Medtronic, Tandem and Insulet possess substantially greater resources in insulin pumps
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beta Bionics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.